Berberine alleviates experimental colitis by enhancing gut-microbiota-dependent intestinal barrier function and suppressing gasdermin D activation

Figure 1 Berberine dose-dependently alleviated dextran sulfate sodium-induced colitis. A: Design of the animal experiment; B: Percentage change in body weight; C: Disease activity index scores; D: Colon images; E: Colon length; F: Spleen weight; G: Micrographs of hematoxylin and eosin-stained colon tissue; H: Histopathological scores. The data shown are the mean ± SEM (n = 5-8). ^aP < 0.05, ^bP < 0.01, and ^cP < 0.001. Berb-L: Berberine low-dose group; Berb-H: Berberine high-dose group; PBS: Phosphate-buffered saline; DSS: Dextran sulfate sodium; CON: Control; DAI: Disease activity index.